Last reviewed · How we verify
NCT02777502
Effects of Cannabidiol on Marijuana-seeking in Humans
trial in Marijuana Abuse in 30 participants. Completed in 31 January 2019.
31 January 2019
Quick facts
| Lead sponsor | Wayne State University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 January 2016 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 January 2019 |
| Sites | 1 location across United States |
Conditions studied
- Marijuana Abuse — all drugs for Marijuana Abuse →
Sponsor
Wayne State University
Who can join
Adults 21 to 45, any sex, with Marijuana Abuse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the proposed study is to investigate the effectiveness of cannabidiol for reducing marijuana seeking in non-treatment seeking volunteers. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) present in marijuana that alters some of the effects of marijuana. Assess the ability of acute smoked CBD pretreatment to reduce marijuana-seeking behavior and increase price-elasticity of marijuana demand.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02777502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Marijuana Abuse
Currently open trials in the same condition.
- NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
Other Wayne State University trials
Trials by the same sponsor.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
- NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
- NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
- NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02777502 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wayne State University
- Last refreshed: 25 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02777502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing